RET Rearrangements May Be Drivers in Cabozantinib-treated Patients With Lung Cancer

Share this content:
Among patients with RET-arranged lung cancer treated with cabozantinib, RET rearrangements may be actionable drivers.
Among patients with RET-arranged lung cancer treated with cabozantinib, RET rearrangements may be actionable drivers.

Among patients with RET-arranged lung cancer treated with cabozantinib, RET rearrangements may be actionable drivers, according to a study published in The Lancet Oncology.1

In a prospective phase 2 trial, researchers led by Alexander Drilon, MD, of the Memorial Sloan Kettering Cancer Center in New York, New York, evaluated 26 patients who had RET-rearranged lung adenocarcinoma treated with cabozantinib to assess for overall response and activity. Twenty-five patients were deemed assessable.

Partial responses were observed in 7 of the 25 patients, and the most common fusion type–KIF5B-RET–was found in 16 patients.

Grade 3 treatment-related adverse events among the 26 patients given cabozantinib included lipase elevation (15%), increased alanine aminotransferase (8%), increased aspartate aminotransferase (8%), decreased platelet count (8%), and hypophosphatemia (8%).

RELATED: Non-Small Cell Lung Cancer Treatment Regimens

“An improved understanding of tumor biology and novel therapeutic approaches will be needed to improve outcomes with RET-directed targeted treatment,” the authors conclude.

Reference

  1. Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016 Nov 4. doi: 10.1016/S1470-2045(16)30562-9 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters